Clinical Trial Update: Open-label Study of Adalimumab in Japanese Subjects With Hidradenitis Suppurativa [Phase 3]

View source ↗

Summary

Open-label Phase 3 trial evaluating adalimumab in Japanese subjects with hidradenitis suppurativa has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hidradenitis Suppurativa

Drugs mentioned

• ADALIMUMAB (ADALIMUMAB-AATY)

Snippet

Sponsor: AbbVie | Conditions: Hidradenitis Suppurativa | Phase 3 | Status: COMPLETED | Results posted: 2019-02-27